Chinese Pharmaceutical Company To Acquire Israeli Medtech Firm

November 22, 2017 | The Shenzhen-listed, China-based pharmaceutical firm Chengdu Kanghong Pharma Group will acquire Israeli medtech company IOPtima in four stages. BioLight Life Sciences, the parent company of IOPtima, announced the acquisition through the Tel Aviv Stock Exchange. In the first stage, Chengdu Kanghong Pharma will buy 19% of IOPtima’s stock for $7 million. Chengdu Kanghong Pharma board of directors already announced they intended to invest in the company in October in a Shenzhen Stock Exchange filing. In later stages, the Chinese pharmaceutical company will buy out the Tel Aviv-based medtech firm’s current shareholders. Founded in Tel Aviv in 2005, IOPtima is a maker of minimally-invasive surgical ophthalmic devices.